Breaking News

Evotec, Fraunhofer In Joint Discovery Alliance

July 8, 2014

Expands Evotec's drug discovery platform

Evotec has entered an exclusive strategic collaboration with the Fraunhofer Institute for internal and external drug discovery projects in several disease areas using a combination platforms from both organizations. The alliance expands Evotec's drug discovery platform with access to a range of platforms and capabilities to use on its own projects and for customers and partners.
 
Dr. Werner Lanthaler, chief executive officer of Evotec, said, "We are looking forward to partner with Fraunhofer IME and are excited about the potential of this alliance. The IME has an impressive track record for product development and provides an ideal basis for collaborating with one of the strongest science organizations in Germany and beyond. This adds another footprint in Europe of our EVT Innovate programs as we have with U.S.-based academic institutions."

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016